Das Bild zeigt einen Arzt, der bei einer jungen Patientin eine Augenuntersuchung durchführt.

Prof. Dr. med. Daniel C. Baumgart

Sie befinden sich hier:

Zur Arbeitsgruppe

... gelangen Sie mit einem Klick hier!

Zur Sprechstunde

... gelangen Sie mit einem Klick hier

Social Media

Folgen Sie wissenschaftlichen Publikationen zum Thema Immunologie und entzündliche Darmerkrankungen auf Twitter Facebook WordPress

Prof. Dr. med. Daniel C. Baumgart, MBA, FACP, AGAF

Keine Ergebnisse? Nutzen Sie bitte auch unsere zentrale Suche.

Berufliche Qualifikationen

Internist, Gastroenterologe, Proktologe, Ernährungsmediziner. Facckunde für Medizinische Tumortherapie, Rettungsmedizin, Strahlenschutz in der Röntgendiagnostik einschließlich Interventionen. Speziell zertifiziert zur Behandlung chronisch-entzündlicher Darmerkrankungen und onkologischer Erkrankungen durch die Deutsche Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS), Zertifizierter EFQM® (European Foundation for Quality Management) Assessor.

Schwerpunkte

  • Immunologische, entzündliche und infektiöse Erkrankungen (z.B. chronisch entzündliche Darmerkrankungen, Morbus Crohn, Colitis ulcerosa, Zöliakie, Autoimmunenteropathie, Immundefekte (Ig-Mangel, CVID, IPEX Syndrom)
  • Klinische Immunologie und Transplantationsmedizin
  • Optische Detektion und bilgeführte Intervention mit neuen Methoden der diagnostischen und interventionellen Endoskopie (z.B. Konfokale Lasermikroskopie (Video: Endomikroskopie), Endozytoskopie, Chromoendoskopie) und der Sonographie (Ultraschall) / Darmsonografie
  • Entwicklung der MR und Sonographie gestützten Elastographie in der Gastroenterologie und Hepatologie
  • Maligne Komplikationen gastrointestinaler Erkrankungen
  • Mukosaimmunologie: speziell dendritische Zellen, innate und adaptive Immunität, mikrobielle Erkennung fungaler vs. bakterieller Antigene
  • Regulation der intestinalen Barriere
  • Telemedizin, eHealth, Data Mining, Big Data PDAs, Smartphones
  • Personalisierte Medizin / Systemmedizin

Curriculum vitae

1988-1994 Studium der Humanmedizin an der Medizinischen Fakultät (Charité) der Humboldt-Universität zu Berlin, der Universität Basel und der Bayerischen Julius Maximilians Universität Würzburg
1993 Promotion an der Charité mit magna cum laude
1994-1996 Arzt und Wissenschaftlicher Mitarbeiter, Medizinische Klinik der Charité
1996-1998 DAAD und DFG Post-Doctoral Research Fellow, University of Pennsylvania Medical Center, Center for Molecular Studies in Digestive and Liver Disease in Philadelphia, USA
1997 US Staatsexamen (US Medical Licensing Exam USMLE I, II, III)
1998- Uneingeschränkte US Berufslizenz (Unrestricted License to Practice Medicine and Surgery)
1998-2000 Medical Resident, Department of Medicine, Georgetown University Medical Center, Washington, DC: Ärztliche Tätigkeit im Rahmen des International Faculty Development Programs am Georgetown University Medical Center, Lombardi Cancer Center, National Institute of Allergy and Infectious Diseases (NIAID) der National Institutes of Health (NIH), Inova Fairfax Hospital, Virginia Hospital Center - Arlington, US Public Health Service und Veterans Affairs Medical Center
2000-2003 Arzt und Wissenschaftlicher Mitarbeiter, Medizinische Klinik der Charité
2002 Abschluß der Facharztausbildung Innere Medizin
2003 Abschluß der Weiterbildung im Schwerpunkt Gastroenterologie und Hepatologie
2004 Ernennung zum Oberarzt
2005 Abschluß des Habilitationsverfahrens und venia legendi für das Fach Innere Medizin
2005 European Board of Gastroenterology and Hepatology (FEBGH)
2012-2014 Zusatzstudium mit Abschluß MBA Healthcare Management mit "sehr gut"
2015- Fellow, Berlin Institute of Health (BIH) gefördert von der StiftungCharité

Forschungsförderung (Drittmittelgeber)

  • American Gastroenterological Association (AGA)
  • American College of Physicians (ACP)
  • American Society for Gastrointestinal Endoscopy (ASGE)
  • Bundesministerium für Bildung und Forschung (BMBF)
  • Deutsche Morbus Crohn / Colitis ulcerosa Vereinigung (DCCV)
  • Deutscher Akademischer Austauschdienst (DAAD)
  • Deutsche Forschungsgemeinschaft (DFG)
  • Eli & Edythe L. Broad Foundation, Los Angeles, CA, USA
  • Fritz Bender Stiftung, München
  • StiftungCharité
  • VolkswagenStiftung
  • Universitäre Forschungsförderung der Charité

Mitgliedschaften in Fachgesellschaften

  • Ärztekammer Berlin
  • Freunde und Förderer des Deutschen Akademischen Austauschdienstes (DAAD)
  • American Medical Association (AMA)
  • American College of Physicians (ACP)
  • American Gastroenterological Association (AGA)
  • American Society of Gastrointestinal Endoscopy (ASGE)
  • Deutsche Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS)
  • Gesellschaft für Hepatologie und Gastroenterologie Berlin-Brandenburg (GGHBB)
  • Deutsche Arbeitsgemeinschaft für chronisch entzündliche Darmerkrankungen (DACED)
  • Deutscher Hochschulverband (DHV)
  • Kompetenznetz Darmerkrankungen (KN CED)
  • German Inflammatory Bowel Disease Study Group (GISG)
  • New Traditions Network (US Department of State)
  • Transatlantic Forum (Herbert Quandt Stiftung)
  • World Young Leaders Network
  • Universities of the Future Projekt
  • Junge Charité

Wissenschaftliche Preise und Ehrungen

1996 Auslandsstipendium für promovierte Nachwuchswissenschaftler des Deutschen Akademischen Austauschdienstes (DAAD)
1997 Forschungsstipendium der Deutschen Forschungsgemeinschaft (DFG)
1998 Recognition as Outstanding Academic Teacher Georgetown University Medical Center
2005 American Medical Association Physician's Recognition Award
2005 Emerging Leader in Gastroenterology
2006 HP Mobile Technology for Teaching in Higher Education Grant Award
2007 World Young Leader (Herbert Quandt Stiftung)
2010 Offen für Außergewöhnliches VolkswagenStiftung
2013 - FOCUS Top Mediziner (seit 2013 jährlich gewählt)
2012 Forschungspreis der Deutschen Morbus Crohn / Colitis ulcerosa Vereinigung (DCCV) für patientenorientierte Forschung
2013 Elected Fellow of the American College of Physicians (FACP)
2014 Elected Fellow of the American Gastroenterological Association (AGAF)

Gutachterliche Tätigkeit

Zeitschriften

Editorial Boards

  • Editorial Consultant: The Lancet
  • Section Editor: Inflammatory Bowel Diseases
  • Member, Editorial Board: Gut
  • Member, Editorial Board: Recent Patents on Anti-Cancer Drug Discovery

Ad-hoc Reviewer für

  • Annals of the Rheumatic Diseases
  • British Journal of Surgery
  • Biomed Central
  • Clinical Gastroenterology and Hepatology
  • Clinical Pharmacology and Therapeutics
  • Deutsches Ärzteblatt (German Medical Weekly)
  • Digestive Surgery
  • Diseases of the Colon and Rectum
  • Drugs of Today
  • Endoscopy
  • European Journal of Pediatrics
  • European Journal of Gastroenterology and Hepatology
  • Expert Review of Molecular Diagnostics
  • Future Drugs
  • Frontiers in Bioscience
  • Gastroenterology
  • Gastrointestinal Endoscopy
  • Gut
  • Human Immunology
  • Inflammatory Bowel Diseases
  • Journal of Crohn's and Colitis
  • Journal of Clinical Immunology
  • Immunobiology
  • JAMA - Journal of the American Medical Association
  • Molecular Nutrition and Food Research
  • Mucosal Immunology
  • New England Journal of Medicine
  • Nutrition
  • Pediatrics
  • Pharmacogenomics
  • Recent Patents on Anti-Infective Drug Discovery
  • Recent Patents on Anti-Cancer Drug Discovery
  • The American Journal of Clinical Dermatology
  • The American Journal of Gastroenterology
  • The American Journal of Physiology
  • The Journal of Immunology
  • The Journal of Clinical Investigation
  • The Lancet
  • The Lancet Infectious Diseases
  • The New England Journal of Medicine
  • Word Journal of Gastroenterology
  • Zeitschrift für Gastroenterologie

 

Institutionen

  • Deutsche Forschungsgemeinschaft (DFG)
  • The French National Research Agency / L'Agence nationale de la recherche (ANR), Paris, France
  • Cochrane Library Special Interest Group Inflammatory Bowel Disease
  • The Wellcome Trust, London, UK
  • Rektorenkonferenz der Schweizer Universitäten / Rectors' Conference of the Swiss Universities (crus.ch)
  • Health Research Board / An Bord Taighde Slante, Dublin, Ireland
  • Biomedical Research Council (BMRC) and Ministry of Health's National Medical Research Council (NMRC) of Singapore
  • The Eli & Edythe Broad Foundation for Medical Research in Inflammatory Bowel Disease, Los Angeles, CA, USA
  • ZonMW (The Netherland Organisation für Health Research and Development), Den Haag, The Netherlands
  • Israel Science Foundation (ISF), Jerusalem, Israel
  • United States-Israel Binational Science Foundation (BSF), Jerusalem, Israel
  • Academy of Finland (Suomen Akatemia, Terveyden tutkimuksen yksikkö), Helsiniki, Finland
  • FWF - Der Wissenschaftsfond, Wien, Österreich
  • AGA Institute Immunology, Microbiology & Inflammatory Bowel Disease Council
  • Drug Safety Institute, Miami, FL, USA
  • Deutsche Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS)
  • Ärztlicher Beirat Uni-Med Science Verlag, Bremen, Boston

Kooperationspartner (Auswahl)

  • Prof. Dr. Richard S. Blumberg, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
  • Prof. Dr. Martin von Bergen, Helmoholtz Zentrum für Umweltforschung, Leipzig
  • Prof. Dr. Andreas Radbruch, Deutsches Rheumaforschungszentrum Berlin
  • Prof. Dr. Michael Blaut, Deutsches Institut für Ernährungsforschung (DIfE) Potsdam
  • Prof. Stefan Koelsch, Department of Biological and Medical Psychology, Faculty of Psychology, University of Bergen, Norway
  • Dr. Daniel Kolarich / Prof. Dr. Peter H. Seeberger, Max Planck Institut für Kolloid- und Grenzflächenforschung, Potsdam
  • Prof. Frederic Geissmann, Center for Molecular and Cellular Biology of Inflammation - CMCBI, King's College London, UK
  • Dr. Anna S. Sörensen, Clinical Immunology and Allergology, Karolinska Institutet, Solna, Stockholm

Publikationen in wissenschaftlichen Journalen

   1. Baumgart DC, Gerl H, Dorner T. Complete heart block caused by primary Sjogren's syndrome and hypopituitarism. Ann Rheum Dis. 1998;57(10):635.
2. Baumgart DC, McVay LD, Carding SR. Mechanisms of immune cell-mediated tissue injury in inflammatory bowel disease (Review). Int J Mol Med. 1998;1(2):315-32.
3. Baumgart DC, Olivier WA, Reya T, Peritt D, Rombeau JL, Carding SR. Mechanisms of intestinal epithelial cell injury and colitis in interleukin 2 (IL2)-deficient mice. Cell Immunol. 1998;187(1):52-66.
4. Baumgart DC, Ventz M, Wermke W. [18-year-old patient with hypercalcemia, hypophosphatemia, nephrocalcinosis and normal iPTH values. Primary hyperparathyroidism]. Internist (Berl). 1998;39(4):403-8.
5. Contractor NV, Bassiri H, Reya T, Park AY, Baumgart DC, Wasik MA, et al. Lymphoid hyperplasia, autoimmunity, and compromised intestinal intraepithelial lymphocyte development in colitis-free gnotobiotic IL-2-deficient mice. J Immunol. 1998;160(1):385-94.
6. Macartney KK, Baumgart DC, Carding SR, Brubaker JO, Offit PA. Primary murine small intestinal epithelial cells, maintained in long-term culture, are susceptible to rotavirus infection. J Virol. 2000;74(12):5597-603.
7. Telega GW, Baumgart DC, Carding SR. Uptake and presentation of antigen to T cells by primary colonic epithelial cells in normal and diseased states. Gastroenterology. 2000;119(6):1548-59.
8. Baumgart DC, Dignass AU. [Intestinal gene regulation by commensal microflora. Remote control from within?]. Z Gastroenterol. 2001;39(9):815-7.
9. Baumgart DC, Dignass AU. Intestinal barrier function. Curr Opin Clin Nutr Metab Care. 2002;5(6):685-94.
10. Baumgart DC, Dignass AU. Shingles following infliximab infusion. Ann Rheum Dis. 2002;61(7):661.
11. Baumgart DC, Dignass AU. [Mucosal dendritic cells: reaching out for the unknown (antigen)]. Z Gastroenterol. 2002;40(5):375-7.
12. Baumgart DC, Dignass AU. [Tacrolimus (FK506) in refractory ulcerative colitis: an alternative to proctocolectomy?]. Z Gastroenterol. 2003;41(5):478-9.
13. Baumgart DC, Gerl H. Photo quiz. Obesity and daytime sleepiness. Prader-Willi syndrome. Am Fam Physician. 2003;68(1):151-2.
14. Baumgart DC, Wiedenmann B, Dignass AU. [Biologic therapy of inflammatory bowel disease]. Z Gastroenterol. 2003;41(10):1017-32.
15. Baumgart DC, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther. 2003;17(10):1273-81.
16. Baumgart DC, Dignass AU. Current biological therapies for inflammatory bowel disease. Curr Pharm Des. 2004;10(32):4127-47.
17. Baumgart DC, Wiedenmann B, Dignass AU. Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus (FK506) in ulcerative colitis. Inflamm Bowel Dis. 2004;10(4):421-4.
18. Cruickshank SM, McVay LD, Baumgart DC, Felsburg PJ, Carding SR. Colonic epithelial cell mediated suppression of CD4 T cell activation. Gut. 2004;53(5):678-84.
19. Dignass AU, Baumgart DC, Sturm A. Review article: the aetiopathogenesis of inflammatory bowel disease--immunology and repair mechanisms. Aliment Pharmacol Ther. 2004;20 Suppl 4:9-17.
20. Baumgart DC. Personal digital assistants in health care: experienced clinicians in the palm of your hand? Lancet. 2005;366(9492):1210-22.
21. Baumgart DC, Metzke D, Schmitz J, Scheffold A, Sturm A, Wiedenmann B, et al. Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells. Gut. 2005;54(2):228-36.
22. Baumgart DC, Sturm A, Wiedenmann B, Dignass AU. Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis. Gut. 2005;54(12):1822-3.
23. Baumgart DC, Veltzke-Schlieker W, Wiedenmann B, Hintze RE. Successful recanalization of a completely obliterated esophageal stricture by using an endoscopic rendezvous maneuver. Gastrointest Endosc. 2005;61(3):473-5.
24. Baumgart DC, Vierziger K, Sturm A, Wiedenmann B, Dignass AU. Mesalamine promotes intestinal epithelial wound healing in vitro through a TGF-beta-independent mechanism. Scand J Gastroenterol. 2005;40(8):958-64.
25. Baumgart DCV-S, W.; Wiedenmann, B.; Hintze, R.E. Successful recanalization of a completely obliterated esophageal stricture by using an endoscopic rendezvous maneuver. Gastrointest Endosc. 2005;61(3):473-5.
26. Baumgart DCV-S, W.; Wiedenmann, B. Successful recanalization of a completely obliterated esophageal stricture by using an endoscopic rendezvous maneuver. Gastrointest Endosc. 2005;62(4):648.
27. Dignass AU, Baumgart DC. New treatment strategies in Crohn's disease: Step-up versus top-down. Verdauungskrankheiten. 2005;23(4):186-91.
28. Sturm A, Baumgart DC, d'Heureuse JH, Hotz A, Wiedenmann B, Dignass AU. CXCL8 modulates human intestinal epithelial cells through a CXCR1 dependent pathway. Cytokine. 2005;29(1):42-8.
29. Sturm A, Rilling K, Baumgart DC, Gargas K, Abou-Ghazale T, Raupach B, et al. Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect Immun. 2005;73(3):1452-65.
30. Andresen VB, D.C. Role of probiotics in the treatment of irritable bowel syndrome: potential mechanisms and current clinical evidence. International Journal of Probiotics & Prebiotics. 2006;1(1):11-8.
31. Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. Am J Gastroenterol. 2006;101(5):1048-56.
32. Baumgart DCT, B.T., Dignass, A. Therapie chronisch-entzündlicher Darmerkrankungen mit Biologika und Immunmodulatoren. D Bay Int. 2006;26(3):144-8.
33. Grabig A, Paclik D, Guzy C, Dankof A, Baumgart DC, Erckenbrecht J, et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Infect Immun. 2006;74(7):4075-82.
34. Tanczos BT, Baumgart DC. [Infliximab for the management of pyoderma gangrenosum in inflammatory bowel disease: one for all?]. Z Gastroenterol. 2006;44(7):609-10.
35. Baumgart DC. Recognition and appropriate management of dysplasia-associated lesions or masses in inflammatory bowel disease--experience does matter. Gastrointest Endosc. 2007;66(3):530-2.
36. Baumgart DC, Buning C, Geerdts L, Schmidt HH, Genschel J, Fiedler T, et al. The c.1-260C>T promoter variant of CD14 but not the c.896A>G (p.D299G) variant of toll-like receptor 4 (TLR4) genes is associated with inflammatory bowel disease. Digestion. 2007;76(3-4):196-202.
37. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369(9573):1627-40.
38. Baumgart DC, Fischer A. Virchow's node. Lancet. 2007;370(9598):1568.
39. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369(9573):1641-57.
40. Buning C, Durmus T, Molnar T, de Jong DJ, Drenth JP, Fiedler T, et al. A study in three European IBD cohorts confirms that the ATG16L1 c.898A>G (p.Thr300Ala) variant is a susceptibility factor for Crohn's disease. J Crohns Colitis. 2007;1(2):70-6.
41. Buning C, Schmidt HH, Molnar T, De Jong DJ, Fiedler T, Buhner S, et al. Heterozygosity for IL23R p.Arg381Gln confers a protective effect not only against Crohn's disease but also ulcerative colitis. Aliment Pharmacol Ther. 2007;26(7):1025-33.
42. Schott E, Paul F, Wuerfel JT, Zipp F, Rudolph B, Wiedenmann B, et al. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a. World J Gastroenterol. 2007;13(26):3638-40.
43. Weylandt KH, Kang JX, Wiedenmann B, Baumgart DC. Lipoxins and resolvins in inflammatory bowel disease. Inflamm Bowel Dis. 2007;13(6):797-9.
44. Baumgart DC. What's new in inflammatory bowel disease in 2008? World J Gastroenterol. 2008;14(3):329-30.
45. Baumgart DC, Macdonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev. 2008(3):CD007216.
46. Berndt U, Philipsen L, Bartsch S, Wiedenmann B, Baumgart DC, Hammerle M, et al. Systematic high-content proteomic analysis reveals substantial immunologic changes in colorectal cancer. Cancer Res. 2008;68(3):880-8.
47. Buning C, Schmidt HH, Molnar T, Drenth JP, Fiedler T, Gentz E, et al. No association of the CARD8 (TUCAN) c.30T>A (p.C10X) variant with Crohn's disease: a study in 3 independent European cohorts. Inflamm Bowel Dis. 2008;14(3):332-7.
48. Niesner U, Albrecht I, Janke M, Doebis C, Loddenkemper C, Lexberg MH, et al. Autoregulation of Th1-mediated inflammation by twist1. J Exp Med. 2008;205(8):1889-901.
49. Paul F, Pfueller CF, Wuerfel JT, Egerer K, Tanczos B, Baumgart DC, et al. Celiac antibodies in the diagnostic workup of white matter lesions. Neurology. 2008;71(3):223-5.
50. Baumgart DC. The diagnosis and treatment of Crohn's disease and ulcerative colitis. Dtsch Arztebl Int. 2009;106(8):123-33.
51. Baumgart DC, Lowder JN, Targan SR, Sandborn WJ, Frankel MB. Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease. Am J Gastroenterol. 2009;104(4):868-76.
52. Baumgart DC, Thomas S, Przesdzing I, Metzke D, Bielecki C, Lehmann SM, et al. Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease. Clin Exp Immunol. 2009;157(3):423-36.
53. Habbel P, Weylandt KH, Lichopoj K, Nowak J, Purschke M, Wang JD, et al. Docosahexaenoic acid suppresses arachidonic acid-induced proliferation of LS-174T human colon carcinoma cells. World J Gastroenterol. 2009;15(9):1079-84.
54. Hasper D, Schefold JC, Baumgart DC. Management of severe abdominal infections. Recent Pat Antiinfect Drug Discov. 2009;4(1):57-65.
55. Pohl H, Rosch T, Tanczos BT, Rudolph B, Schluns K, Baumgart DC. Endocytoscopy for the detection of microstructural features in adult patients with celiac sprue: a prospective, blinded endocytoscopy-conventional histology correlation study. Gastrointest Endosc. 2009;70(5):933-41.
56. Thomas S, Przesdzing I, Metzke D, Schmitz J, Radbruch A, Baumgart DC. Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation. Clin Exp Immunol. 2009;156(1):78-87.
57. Baumgart DC. How many lives does an ulcerative colitis patient have? Lancet. 2010;376(9744):928.
58. Baumgart DC. CB-01-05-MMX, a novel oral controlled-release low molecular weight heparin for the potential treatment of ulcerative colitis. Curr Opin Investig Drugs. 2010;11(5):571-6.
59. Baumgart DC. Veto on vedolizumab (MLN0002) for Crohn's disease. Inflamm Bowel Dis. 2010;16(3):537-8.
60. Baumgart DC, Targan SR, Dignass AU, Mayer L, van Assche G, Hommes DW, et al. Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2010;16(4):620-9.
61. Dignass A, Van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel JF, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis. 2010;4(1):28-62.
62. Dignass AU, Eriksson A, Kilander A, Pukitis A, Rhodes JM, Vavricka S. Clinical trial: five or ten cycles of granulocyte-monocyte apheresis show equivalent efficacy and safety in ulcerative colitis. Aliment Pharmacol Ther. 2010;31(12):1286-95.
63. Muller T, Baumgart DC. [Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: the more the better?]. Z Gastroenterol. 2010;48(5):569-70.
64. Sandborn WJ, Colombel JF, Frankel M, Hommes D, Lowder JN, Mayer L, et al. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut. 2010;59(11):1485-92.
65. Schirbel A, Reichert A, Roll S, Baumgart DC, Buning C, Wittig B, et al. Impact of pain on health-related quality of life in patients with inflammatory bowel disease. World J Gastroenterol. 2010;16(25):3168-77.
66. Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis. 2010;4(1):7-27.
67. Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis. 2010;4(1):63-101.
68. [Adherence to the H1N1 vaccination recommendation in patients with Crohn's disease or ulcerative colitis]. Dtsch Med Wochenschr. 2011;136(18):939-43.
69. Baumgart DC. Foreword. European Gastroenterology and Hepatology Review. 2011;7(3):152-3.
70. Baumgart DC. Endoscopic surveillance in Crohn's disease and ulcerative colitis: who needs what and when? Dig Dis. 2011;29 Suppl 1:32-5.
71. Baumgart DC. Smartphones in clinical practice, medical education, and research. Arch Intern Med. 2011;171(14):1294-6.
72. Baumgart DC. Extended colonic release low-molecular weight heparin (LMWH) not ready for use in ulcerative colitis. Evid Based Med. 2011;16(3):71-2.
73. Baumgart DC, Bernstein CN, Abbas Z, Colombel JF, Day AS, D'Haens G, et al. IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010--Inflammatory Bowel Disease Task Force meeting. Inflamm Bowel Dis. 2011;17(2):639-44.
74. Baumgart DC, Grittner U, Steingraber A, Azzaro M, Philipp S. Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients. Inflamm Bowel Dis. 2011;17(12):2512-20.
75. Baumgart DC, Metzke D, Guckelberger O, Pascher A, Grotzinger C, Przesdzing I, et al. Aberrant plasmacytoid dendritic cell distribution and function in patients with Crohn's disease and ulcerative colitis. Clin Exp Immunol. 2011;166(1):46-54.
76. Eckardt AJ, Baumgart DC. Viral gastroenteritis in adults. Recent Pat Antiinfect Drug Discov. 2011;6(1):54-63.
77. Thomas S, Metzke D, Schmitz J, Dorffel Y, Baumgart DC. Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis. Am J Physiol Gastrointest Liver Physiol. 2011;301(6):G1083-92.
78. Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366(7):601-9.
79. Autenrieth DM, Baumgart DC. Toxic megacolon. Inflamm Bowel Dis. 2012;18(3):584-91.
80. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet. 2012;380(9853):1590-605.
81. Buning C, Geissler N, Prager M, Sturm A, Baumgart DC, Buttner J, et al. Increased small intestinal permeability in ulcerative colitis: rather genetic than environmental and a risk factor for extensive disease? Inflamm Bowel Dis. 2012;18(10):1932-9.
82. Louis E, Baumgart DC, Ghosh S, Gomollon F, Hanauer S, Hart A, et al. What changes in inflammatory bowel disease management can be implemented today? J Crohns Colitis. 2012;6 Suppl 2:S260-7.
83. Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012;380(9853):1606-19.
84. Pohl H, Tanczos BT, Rudolph B, Meining A, Khalifa AC, Rosch T, et al. Probe-based confocal laser microscopy identifies criteria predictive of active celiac sprue. Dig Dis Sci. 2012;57(2):451-7.
85. Prager M, Buttner J, Haas V, Baumgart DC, Sturm A, Zeitz M, et al. The JAK2 variant rs10758669 in Crohn's disease: altering the intestinal barrier as one mechanism of action. Int J Colorectal Dis. 2012;27(5):565-73.
86. Prantera C, Lochs H, Grimaldi M, Danese S, Scribano ML, Gionchetti P, et al. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology. 2012;142(3):473-81 e4.
87. Thomas S, Baumgart DC. Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology. 2012;20(1):1-18.
88. Baumgart DC, Sandborn WJ. Erratum: Crohn's disease (The Lancet (2012) 380 (1590-605)). The Lancet. 2013;381(9862):204.
89. Fischer A, Gluth M, Pape UF, Wiedenmann B, Theuring F, Baumgart DC. Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-alpha on tight junction proteins and signaling pathways in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2013;304(11):G970-9.
90. Kohnke T, Gomolka B, Bilal S, Zhou X, Sun Y, Rothe M, et al. Acetylsalicylic Acid reduces the severity of dextran sodium sulfate-induced colitis and increases the formation of anti-inflammatory lipid mediators. Biomed Res Int. 2013;2013:748160.
91. Muller T, Beutler C, Pico AH, Otten M, Durr A, Al-Abadi H, et al. Increased T-helper 2 cytokines in bile from patients with IgG4-related cholangitis disrupt the tight junction-associated biliary epithelial cell barrier. Gastroenterology. 2013;144(5):1116-28.
92. Panes J, Bouhnik Y, Reinisch W, Stoker J, Taylor SA, Baumgart DC, et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis. 2013;7(7):556-85.
93. Pohl H, Wrobel K, Bojarski C, Voderholzer W, Sonnenberg A, Rosch T, et al. Risk factors in the development of esophageal adenocarcinoma. Am J Gastroenterol. 2013;108(2):200-7.
94. Rutgeerts PJ, Fedorak RN, Hommes DW, Sturm A, Baumgart DC, Bressler B, et al. A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut. 2013;62(8):1122-30.
95. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369(8):711-21.
96. Fischer A, Gluth M, Weege F, Pape UF, Wiedenmann B, Baumgart DC, et al. Glucocorticoids regulate barrier function and claudin expression in intestinal epithelial cells via MKP-1. Am J Physiol Gastrointest Liver Physiol. 2014;306(3):G218-28.
97. Gasche C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, Buning C, et al. Ferric Maltol Is Effective in Correcting Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: Results from a Phase-3 Clinical Trial Program. Inflamm Bowel Dis. 2014.
98. Gerlach UA, Vrakas G, Reddy S, Baumgar DC, Neuhaus P, Friend PJ, et al. Chronic intestinal failure after crohn disease: when to perform transplantation. JAMA Surg. 2014;149(10):1060-6.
99. Papanikolaou IS, van der Voort IR, Chopra SS, Seebauer CJ, Rump J, Papas MG, et al. MRI-guided percutaneous transhepatic cholangiodrainage: feasibility study in a porcine model. Scand J Gastroenterol. 2014;49(6):722-6.
100. Prager M, Durmus T, Buttner J, Molnar T, de Jong DJ, Drenth JP, et al. Myosin IXb variants and their pivotal role in maintaining the intestinal barrier: a study in Crohn's disease. Scand J Gastroenterol. 2014;49(10):1191-200.
101. Vermeire S, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014;384(9940):309-18.
102. Krupka N, Baumgart DC. Designing biologic selectivity for inflammatory bowel disease - role of vedolizumab. Drug Des Devel Ther. 2015;9:147-54.
103. Baumgart DC, Müller HP, Grittner U, Metzke D, Fischer A, Guckelberger O, Pascher A, Sack I, Vieth M, Rudolph B. US-based Real-time Elastography for the Detection of Fibrotic Gut Tissue in Patients with Stricturing Crohn Disease. Radiology. 2015 Jun;275(3):889-99. doi: 10.1148/radiol.14141929. Epub 2015 Feb 6.
104. Baumgart DC, MacDonald JT, Feagan B. Apheresis for induction and maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2016: in press.
105. Baumgart DC, Wende I, Grittner U. Tablet Computer Based Multimedia Enhanced Medical Training Improves Performance in Gastroenterology and Endoscopy Board Style Exam compared with Traditional Medical Education. Gut. 2015 Jun 29. pii: gutjnl-2015-309895. doi: 10.1136/gutjnl-2015-309895. [Epub ahead of print]
106. Baumgart DC. The human microbiome – role for inflammatory and malignant diseases. Dtsch Med Wochenschr. 2015 Sep;140(19):1451-6. doi: 10.1055/s-0041-103202. Epub 2015 Aug 25.
107. Tew GW, Hackney JA, Gibbons D, Lamb CA, Luca D, Egen JG, Diehl L, Anderson JE, Vermeire S, Mansfield JC, Feagan BG, Panes J, Baumgart DC, Schreiber S, Dotan I, Sandborn WJ, Kirby JA, Irving PM, De Hertogh G, Van Assche GA, Rutgeerts P, O'Byrne S, Hayday A, Keir ME. Identification of colonic αE integrin and granzyme A as etrolizumab-predictive biomarkers in ulcerative colitis. Gastroenterology. 2015 Oct 29. pii: S0016-5085(15)01574-7. doi: 10.1053/j.gastro.2015.10.041. [Epub ahead of print]
108. Schmidt KJ, Müller N, Dignass A, Baumgart DC, Lehnert H, Stange EF, Herrlinger KR, Fellermann K and Büning J. Tacrolimus in steroid-refractory ulcerative colitis – long-term experience in 156 patients. J Crohns Colitis. 2016 Jan;10(1):31-7.
109. Baumgart DC, Le Claire M. The expenditures for academic inpatient care of inflammatory bowel disease patients are almost double compared with average academic gastroenterology and hepatology cases and not fully recovered by diagnosis-related group (DRG) proceeds. PLoS One. 2016 Jan 19;11(1):e0147364. doi: 10.1371/journal.pone.0147364. eCollection 2016.
110. Dignass A, Akbar A, Hart A, Subramanian S, Bommelaer G, Baumgart DC, Grimaud JC, Cadiot G, Makins R, Hoque S, Bouguen G, Bonaz B. Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results. J Crohns Colitis. 2016 Jul;10(7):812-20.
111. Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, Plevy S, Popp J, Cornillie FJ, Lukas M, Danese S, Gionchetti P, Hanauer SB, Reinisch W, Sandborn WJ, Sorrentino D, Rutgeerts P; PREVENT Study Group. Infliximab Reduces Endoscopic, but not Clinical, Recurrence of Crohn's Disease Following Ileocolonic Resection. Gastroenterology. 2016 Jun;150(7):1568-78.
112. Baumgart DC, Bokemeyer B, Drabik A, Stallmach A, Schreiber S; Vedolizumab Germany Consortium. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study. Aliment Pharmacol Ther. 2016 May;43(10):1090-102.
113. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study. Schmidt C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, Howaldt S, Stallmach A, Büning C; AEGIS Study Group. Aliment Pharmacol Ther. 2016 Aug;44(3):259-70.
114. Stallmach A, Langbein C, Atreya R, Bruns T, Dignass A, Ende K, Hampe J, Hartmann F, Neurath MF, Maul J, Preiss JC, Schmelz R, Siegmund B, Schulze H, Teich N, von Arnim U, Baumgart DC, Schmidt C.Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
Aliment Pharmacol Ther. 2016 Dec;44(11-12):1199-1212.
115.  Roggenbuck D, Reinhold D, Baumgart DC, Schierack P, Conrad K, Laass MW. Autoimmunity in Crohn's Disease — A Putative Stratification Factor of the Clinical Phenotype. Adv Clin Chem. 2016;77:77-101.
116. Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016 Sep 24;388(10051):1281-90.
117.  Julsgaard, M, Kjeldsen, J, Baumgart, DC. Vedolizumab Safety in Pregnancy and Newborn Outcomes. Gut. 2017 Jan 10. pii: gutjnl-2016-313444. doi: 10.1136/gutjnl-2016-313444. [Epub ahead of print]
118.  Baumgart DC, Wende I, Grittner U. Tablet Computer Enhanced Training Improves Internal Medicine Exam Performance. PLoS One. 2017 Apr 3;12(4):e0172827.
119.  Autenrieth DM, Baumgart DC. Microbiome and gut inflammation.Dtsch Med Wochenschr. 2017 Feb;142(4):261-266.
120.  Steinhagen PR, Baumgart DC. Fundamentals of the microbiome. Internist (Berl). 2017 Mar 29. doi: 10.1007/s00108-017-0224-1. [Epub ahead of print]
121. D'Haens G, Vermeire S, Vogelsang H, Allez M, Desreumaux P, Van Gossum A, Sandborn WJ, Baumgart DC, Ransohoff RM, Comer GM, Ahmad A, Cataldi F, Cheng J, Clare R, Gorelick KJ, Kaminski A, Pradhan V, Rivers S, Sikpi MO, Zhang Y, Hassan-Zahraee M, Reinisch W, Stuve O. Central nervous system immune surveillance and circulating Β7+CD4 T cells under anti-MAdCAM-1 antibody treatment for Crohn's disease: report of the TOSCA study. JAMA Neurology 2017: submitted.

Bücher

Buchbeiträge

Informationen für Studierende und Lehrende